Intangible Assets

12 Months Ended

Dec. 31, 2013

Notes to Financial Statements

Note 8. Intangible Assets

Intangible assets as of December 31, 2013 and 2012 consisted of the following:

	2013			2012
Licensed patents and patent rights	$	50,000		$	50,000
Patents		41,044			41,004
NuRx licensed technology		13,200			-
Less: accumulated amortization		(67,112	)		(59,024	)
Intangibles, net	$	37,092		$	31,980

Patent under Licensing

The Company licenses patent rights and know-how for certain hemorrhoid treatment pads and related coatings from The Procter & Gamble Company. The five-year license agreement was entered into July 2006 and has a five-year automatic renewal option.  Although the Company renewed the agreement in 2011, payments have been suspended due to the Company’s current financial condition.  The Company has subsequently filed for a patent to address the technology used in its treated miniforms, which was issued during 2013.